Status:
WITHDRAWN
Epacadostat, Idarubicin and Cytarabine (EIC) in AML
Lead Sponsor:
Insel Gruppe AG, University Hospital Bern
Conditions:
AML
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This trial assess the maximum tolerated dose (MTD) and to characterize dose-limiting toxicities (DLTs) of epacadostat when added to the anthracycline/cytarabine combination as first-line induction tre...
Detailed Description
Background and Rationale: Epacadostat (INCB024360) is an Inhibitor of Indoleamine 2,3- dioxygenase 1 (IDO1). Indoleamine 2,3- dioxygenase 1 (IDO1) is a 403 amino acid cytosolic haem enzyme encoded by...
Eligibility Criteria
Inclusion
- AML (according to the 2016 World Health Organization (WHO) classification definition of ≥ 20% blasts; Arber et al, 2016) suitable for intensive treatment (including stem cell transplantation) with a curative intent.
- Patients must be aged \> 18 years, and must have given voluntary written informed consent.
- Women of childbearing potential having a negative serum pregnancy test at screening or at least within 48 hours before start with epacadostat, and willing to use an effective contraceptive method (intrauterine devices, hormonal contraceptives, contraceptive pill, implants, transdermal patches, hormonal vaginal devices, infusions with prolonged release) during the study and for at least 6 months after the last study drug administration
- Men willing to use an effective contraceptive method (eg, condom, vasectomy) during the study and for at least 6 months after the last study drug administration.
Exclusion
- Prior or concurrent malignancy, except for the following: adequately treated basal cell or squamous cell skin cancer, or any other cancer from which the subject has been disease-free for more than 6 months.
- Any previous AML or MDS chemotherapy (with the exception of hydroxyurea/Litalir® for leukocyte control which should be discontinued by the first day of induction chemotherapy
- Treatment with any investigational product within 4 weeks before the first administration of epacadostat (INCB024360)
- Abnormal organ function if not caused by the underlying disease as considered by the treating physician
- Use of immune-suppressive agents for the past 4 weeks before the first administration of epacadostat (INCB024360). For regular use of systemic corticosteroids, subjects may only be included after stepwise discontinuation to be free of steroids for a minimum of 5 days before the first administration of epacadostat (INCB024360)
Key Trial Info
Start Date :
September 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2019
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT03444649
Start Date
September 1 2018
End Date
October 1 2019
Last Update
September 11 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Departement of Medical Oncology, University Hospital Berne
Bern, Switzerland, 3010